APLAR 2022 Highlights

APLAR 2022
Congress Preview
Hong Kong
5–9 December 2022
Steering Committee Introduction
Dear Colleagues,
Welcome to my selection of the highlights to look out for at APLAR 2022.
The learning starts even before APLAR with a pre congress MRI Workshop for Axial SpA on Monday and Tuesday.
Also on Tuesday fellow CSF Steering Committee member Peter Nash chairs the GRAPPA Symposium on axSpA and PsA.
The congress sessions start on Wednesday with a session on What is New in PsA and some interesting abstract
presentations including bimekizumab in PsA, real world data on JAKs from the Hong Kong registry and effects on pain.
The congress session in the afternoon include rapid fire presentations in PsA and nrAxSpA and a session on Emerging
concepts in in Spondyloarthritis which sandwich the EULAR session on remission in RA.
There are also industry supported symposiums on PsA and Jak inhibitors where I will present data as part of the
New Generation symposium supported by Gilead. In the evening there is our own CSF session JAK Inhibition –
Are the Promises Fulfilled? Where colleagues will consider where we are across the range of indications for JAK
inhibitors in rheumatology
Thursday’s programme has a plenary session talk in the morning by CSF Steering Committee Chair Iain McInnes.
There is then a symposium on the advances made in the fields of axSpA and RA. A late session on the holistic
management of PsA rounds of the penultimate day of the conference.
The final day of APLAR 2022 provides a series of abstracts to end the conference. A discussion on the association
between dysbiosis and lymphocyte subsets in PsA accompanies a presentation of the latest BE MOBILE study data.
As always thank you for your continued support.
Kind regards
Professor Tsutomu Takeuchi
SPONSORSHIP AND UNRESTRICTED EDUCATIONAL GRANTS FROM
Register for FREE content at www.cytokinesignalling.com
DEVELOPED UNDER
THE AUSPICES OF THE
Follow us at:
Cytokine Signalling Forum

Key Presentations
Monday 5th December 2022
1000–
1700
MRI WORKSHOP FOR AXIAL SPA DAY 1
Sponsored by UCB
Tuesday 6th December 2022
0900–
1400
0900–
1400
MRI WORKSHOP FOR AXIAL SPA DAY 2
Sponsored by UCB
GRAPPA SYMPOSIUM
Sponsored by UCB
Chair: Peter Nash
Wednesday 7th December 2022
0800–
0900
0800–
0900
1055–
1200
Hall 5G
PSORIATIC ARTHRITIS – WHAT IS NEW?
Chairpersons: Tin Lok Lai and Howe Hwee Siew
Does psoriasis treatment affect PsA development
Alexis Ogdie
Peripheral spondyloarthritis and psoriatic arthritis: results
of the worldwide, cross-sectional ASAS-PerSpA study
Mitsumasa Kishimoto
ABSTRACT SESSION
Chairpersons: Lie Dai and Samina Ghaznavi
Bimekizumab in Patients with Active Psoriatic Arthritis and
an Inadequate Response to TNF Inhibitors: BE COMPLETE
16-Week Efficacy and Safety
Yoshiya Tanaka
Safety of the JAK inhibitors in comparison with
the TNF inhibitors in RA:real world data from the
HK Biologics Registry
Chi Chiu Mok
Application and simplification of the global pain
assessment scale in patients with rheumatoid arthritis
Biyu Shen
Vascular effect of treat to target in early rheumatoid
arthritis patients – a 5uyear prospective study
Huan Meng
OPENING THE DOOR TOWARDS FREEDOM FROM
PSORIATIC ARTHRITIS
Sponsored by Janssen
Chairperson: Peter Nash
PsA pathophysiology and Interleukin 23 inhibitors
Jonathan Sherlock
Hot topics in PsA management
Peter Nash
The unmet needs of PsA management in daily practice –
it’s more than the joints
Dr Ho So
1055–
1200
S423-4
1315–
1455
1335–
1455
Hall 5G
1455–
1610
1640–
1755
THE ROLE OF A NEW-GENERATION JAK
INHIBITOR IN THE TREATMENT OF RHEUMATOID
ARTHRITIS
Sponsored by GILEAD
Chairperson: Tsutomu Takeuchi
The Role of a New-Generation JAK inhibitor in The
Treatment of Rheumatoid Arthritis.
Mitsumasa Kishimoto
RAPID FIRE POSTER PRESENTATIONS
Association of Baseline Characteristics with Minimal
Disease Activity of Guselkumab Treatment in Biologic-
Experienced PsA Patients: Phase IIIb COSMOS Clinical Trial
Masaru Kato
Bimekizumab Improves Signs and Symptoms of Active
Non-Radiographic Axial Spondyloarthritis: 24-Week Results
from the Phase 3 BE MOBILE 1 Study
Huji Xu
EXPANDING KNOWLEDGE ON TOFACITINIB FOR
THE TREATMENT OF RA
Sponsored by Pfizer
Chairperson: Chi Chiu Mok
Tofacitinib in RA: Learnings and implications from recent
efficacy and safety data
Kunihiro Yamaoka
Recent updates and recommendations for the management
of RA: Implications for clinical practice
Andreas Kerschbaumer
Real-world data for advanced RA treatments: Learnings
from Hong Kong
Chi Chiu Mok
EULAR SYMPOSIUM: RHEUMATOID ARTHRITIS
REMISSION – FROM CLINICAL DEFINITIONS TO
IMAGING ASSESSMENT. WHAT IS NEW?
Chairpersons: Yoshiya Tanaka and Lai Shan Tam
EMERGING CONCEPTS IN SPONDYLOARTHRITIS
Chairpersons: James Wei and Simon Stebbings
The gut and spondyloarthritis: emerging evidence
and controversies
Dirk Elewaut
Uveitis and spondyloarthritis: more than meets the eye
Muhammad Haroon
Treat-to-target in spondyloarthritis – data from the APLAR
SpA registry
Lai-Shan Tam
1800–
1900
S421
1800–
1900
S423-4
JAK INHIBITION – ARE THE PROMISES FULFILLED?
Sponsored by The Cytokine Signalling Forum
Chair: Lai-Shan Tam
JAK inhibitors in RA – where do they fit in the
treatment paradigm?
Ernest Choy
The therapeutic landscape of PsA treatment
Peter Nash
Latest overview of the management of axSpA
Hideto Kameda
NO PATIENT LEFT BEHIND: A HOLISTIC APPROACH
TO THE TREATMENT OF PATIENTS WITH SPA
Sponsored by UCB
Chair: James Wei
A Holistic Approach to the Treatment of axSpA
Ho Yin Chung
Management of PsA: Refractory Patients and Continuity
of Treatment
Pui-Ying Leong
Elevating Treatment Targets in SpA
James Wei
Thursday 8th December 2022
0900–
1030
1055–
1200
S423-4
1335–
1455
Hall 5G
PLENARY SESSION 2
Chairpersons: Debashish Danda and Ronald Yip
The AxSpA spectrum – using pathogenesis to apply
therapeutic strategies?
Iain McInnes
2022 updates of RA treatment from Japanese experiences
Tsutomu Takeuchi
RAISING THE BAR FOR PATIENTS WITH SPA:
TREATMENT TARGETS AND A LOOK TO THE FUTURE
Sponsored by UCB
Chair: Huji Xu
Aiming for More Stringent Treatment Targets for Patients
Across the axSpA Spectrum
Huji Xu
Treating to Target in the PsA Clinic
Atul Deodhar
The Evolving Therapeutic Landscape of axSpA and PsA
Huji Xu and Atul Deodhar
BENEFIT: RISK OF JAK INHIBITORS –
WHAT ARE THEIR CLINICAL CONTEXTS?
Sponsored by Abbvie
Chair: Lai-Shan Tam
Clinical context of JAK inhibitors in RA
Kunihiro Yamaoka
1640–
1755
1800–
1900
Hall 5G
2000–
2115
ANKYLOSING SPONDYLITIS –
FROM BENCH TO BEDSIDE
Chairpersons: Jeiro Gu and Sami Salman
Therapies for spondyloarthritis: past, present and future
Iain McInnes
ADVANCES IN THE TREATMENT OF
SPONDYLOARTHRITIS AND RHEUMATOID
ARTHRITIS
Sponsored by Lilly
Chairpersons: Gavin Lee & Carmen Ho
Discussing Spondyloarthritis: Ixekizumab and its relevance
to Clinical Practice
Xenofon Baraliakos
How clinical data and real-world evidence are changing
the treatment of Rheumatoid Arthritis
Yuko Kaneko
HOLISTIC MANAGEMENT OF PSORIATIC
ARTHRITIS – WHERE ARE WE NOW?
Chairpersons: Muhammad Ahmed Saeed and Nazrul Islam
Collaborating with dermatology: practice beyond diagnosing
Kichul Shin
Inflammation and metabolic syndrome: lessons learnt from
psoriatic disease
Muhammad Haroon
Composite measures for PsA outcomes
Katy Leung
Friday 9th December 2022
0800–
0900
0800–
0900
ABSTRACT SESSION
Chairpersons: Shirley Chan and B.G. Dharmanand
Efficacy and safety of bimekizumab in Chinese patients
with active Ankylosing Spondylitis from the Phase 3 study
BE MOBILE 2
Huji Xe
Dysbiosis of the gut microbiota in patients with psoriatic
arthritis is closely related to lymphocyte subsets and
cytokines
Sheng-Xiao Zhang
ABSTRACT SESSION
Chairpersons: Mei Yan Clara Law and Chit Soe
Are we treating to target in spondyloarthritis (SpA)?
a cross sectional analysis from the Asia Pacific League
of Associations for Rheumatology (APLAR) SpA registry
Isaaz Tsz Ho Cheng
Male SpA patients with longer disease duration have less
severe disc degeneration – a propensity-score matched
comparison with the population
Tin Yan Samuel Cheung
Clinical context of JAK inhibitors in SpA
Denis Poddubnyy